Investigating a blood biomarker for pulmonary arterial hypertension
Official title: NOTCH3 ECD as a Serum Biomarker for Pulmonary Arterial Hypertension
Funded at University of California, San Diego · NIH-11135322 · Data updated 2026-11-12
This study is looking at a protein in the blood called NOTCH3 ECD to see if it can help doctors understand how severe pulmonary arterial hypertension (PAH) is in patients, which could improve how the condition is diagnosed and treated.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | July 15, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $552,262 |
| NIH project number | 5R01HL169861-02 |
| Project ID | NIH-11135322 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension.
✕Less likely to help
Patients with other forms of pulmonary hypertension or those without a diagnosis of pulmonary arterial hypertension may not benefit from this research.
What this research studies
This research focuses on understanding the NOTCH3 extracellular domain (ECD) as a potential serum biomarker for pulmonary arterial hypertension (PAH), a serious and progressive lung condition. The study aims to explore how NOTCH3 ECD levels in the blood correlate with the severity of PAH, which could help in diagnosing and monitoring the disease. Researchers will analyze blood samples to determine the relationship between NOTCH3 ECD and the pathological processes involved in PAH, potentially leading to new clinical applications. The findings could enable better patient management and treatment strategies for those affected by this condition.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and treatment options for patients with pulmonary arterial hypertension.
How similar studies have gone: Previous research has shown promising results in using biomarkers for various diseases, suggesting potential success for this novel approach in PAH.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Thistlethwaite, Patricia a — University of California, San Diego
- Study coordinator: Thistlethwaite, Patricia a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.